Samrat Pharmachem Ltd (530125)
The Board considered and adopted the unaudited financial results for the quarter ended June 30, 2026
Q1FY27 results:
Standalone:
Revenue 79.8bn +5.4% y-y (75.7bn)
EBITDA 15.7bn - (derived from Revenue - Expenses)
EBITDA margin 19.7% (20.1%) -40 bps y-y
PAT 0.88bn (loss of 0.23bn last year)
Profit before tax 1.59bn vs 0.21bn last year
Tax expense 0.71bn
Total comprehensive income 0.88bn
Commentary: Company reported profit turnaround in Q1FY27 from loss in Q1FY26
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 530125 — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add 530125 to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Samrat Pharmachem Ltd
Important.
The summary above is generated automatically from Samrat Pharmachem Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.